Overview

Liraglutide 3 mg for Knee Osteoarthritis

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
A randomised, double blind, placebo-controlled, parallel group, and single-centre trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis. Patients will be subjected to a run-in diet intervention phase (week -8 to 0) including a low-calorie diet and dietetic counselling. At week 0 patients will be randomised to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.
Phase:
Phase 4
Details
Lead Sponsor:
Henrik Gudbergsen
Collaborators:
Cambridge Weight Plan Limited
Novo Nordisk A/S
Treatments:
Liraglutide